9 Meters now hopes to start a phase 3 programme for the drug before the end of the year, but the announcement has not been able to reverse a steady decline in its stock price since it reported last ...
Johnson & Johnson has moved a step closer to filing a potential first-in-class therapy for psoriasis after the drug hit the mark in a phase 3 trial. Once-daily oral IL-23 inhibitor icotrokinra ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback